Get the Stockscreener App
188.41
1.47%
2.73
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $188.41, with a volume of 3.24M.
It is up +1.47% in the last 24 hours and up +0.65% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$185.68
Open:
$184.28
24h Volume:
3.24M
Relative Volume:
1.64
Market Cap:
$292.20B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
56.58
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
+7.71%
1M Performance:
+0.65%
6M Performance:
+102.81%
1Y Performance:
+168.89%
1-Day Range:
$184.28
$189.57
1-Week Range:
$175.11
$189.57
52-Week Range:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
188.41 | 287.96B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,208.12 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 589.48B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 429.58B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.66 | 309.84B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.41 | 295.98B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca focuses on long-term oncology strategy, shares anchored in the FTSE 100 - Ad-hoc-news.de
The Breztri Aerosphere from AstraZeneca plctriple therapy aims at severe COPD - Ad-hoc-news.de
AstraZeneca cautious after EU panel vote, shares reflect Tavneos setback - Ad-hoc-news.de
Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today - Kavout | AI
Could This Clinical Milestone Reshape AstraZeneca’s (LSE:AZN) Future? - Kalkine Media
Daiichi Sankyo and AstraZeneca Announce Datroway Recommends for Approval in EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy - marketscreener.com
Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout - Yahoo Finance UK
AstraZeneca updates on pipeline and AI efforts, shares tracked by analysts - Ad-hoc-news.de
AstraZeneca's, Daiichi's Datroway recommended for further EU approval - London South East
AstraZeneca : Datroway recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy - marketscreener.com
Could AstraZeneca (LSE:AZN) Continue Leading the Healthcare Space? - Kalkine Media
ASTRAZENECA : Gets a Buy rating from Jefferies - marketscreener.com
AstraZeneca PLC Actuals & Estimates (LSE:AZN) - TradingView
AstraZeneca PLC ADR Unsponsored Brazilian Depositary Receipt Repr 0.1666 ADR - TradingView
Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note - sharewise.com
AstraZeneca PLC Actuals & Estimates (NYSE:AZN) - TradingView
AstraZeneca outlines next growth phase, shares sit on solid large-cap footing - Ad-hoc-news.de
AZN Stock Quote Price and Forecast - CNN
Enterprise value to EBIT forward of AstraZeneca PLC ADR – BCBA:AZN.CI - TradingView
AstraZeneca reports positive Tagrisso data, shares stay in focus on NASDAQ - Ad-hoc-news.de
Enterprise value to revenue forward of AstraZeneca PLC ADR – BCBA:AZN.CI - TradingView
Why is AstraZeneca (LSE:AZN) holding the spotlight as UK pharma stays firm today? - Kalkine Media
Can AstraZeneca PLC (AZN) Grow Its Rare Disease Portfolio Through Ultomiris Expansion? - Yahoo Finance
AstraZeneca and YMCA target cancer screening gaps in 75 communities - Stock Titan
AstraZeneca’s Next Chapter: What Is Driving Market Attention? - Kalkine Media
AstraZeneca operations and pipeline, shares anchored in FTSE 100 - Ad-hoc-news.de
AstraZeneca consensus stays positive, analysts see upside for the stock - Ad-hoc-news.de
AstraZeneca consensus stays positive, analysts see upside for shares - Ad-hoc-news.de
Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
AstraZeneca advances Tuesday, outperforms market - MarketWatch
AVIP BlackRock Advantage International Equity Portfolio's AstraZeneca PLC(LSE:AZN) Holding History - GuruFocus
AstraZeneca Steadies the FTSE 100 as Healthcare Stays in Focus - Kalkine Media
Is AstraZeneca a growth engine for the FTSE 100 today? - Kalkine Media
AstraZeneca PLC (AZN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Down 14% to below £135, here’s where AstraZeneca’s deeply undervalued share price ‘should’ be trading today - twelfthmagpie.com
AstraZeneca outlines oncology growth priorities, shares supported by robust FTSE 100 role - Ad-hoc-news.de
AstraZeneca refines cancer focus, shares tracked against big pharma peers - Ad-hoc-news.de
AstraZeneca PLC (AZN) Stock Analysis: Robust Growth and Analyst Confidence Propel a 28% Upside Potential - DirectorsTalk Interviews
AstraZeneca PLC (AZN) Valuation: PE, PB & Fair Value Analysis - TradingKey
What's moving AstraZeneca shares as UK pharma stays strong? - Kalkine Media
Why AstraZeneca (LSE:AZN) Is Back In London’s Blue-Chip Debate - Kalkine Media
Could Defensive Demand Keep AstraZeneca [LSE:AZN] in the Healthcare Spotlight as Markets Wobble? - Kalkine Media
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Britannica
AstraZeneca StockSaturday look at long-term growth drivers - Ad-hoc-news.de
AstraZeneca (LSE:AZN) Stock Fair Value Edges Lower After Pipeline And Pricing Debate - Yahoo Finance
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Undervalued After Recent Pullback - Yahoo Finance
AZN News | ASTRAZENECA PLC (NYSE:AZN) - ChartMill
Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
AstraZeneca slides Thursday, underperforms market - MarketWatch
AstraZeneca rallies Wednesday, outperforms market - MarketWatch
AstraZeneca (AZN) Advances Oral GLP-1 Receptor Agonist Elecoglipron to Phase III Trials - Yahoo Finance
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):